Mostrando 10 resultados de: 50
Filtros aplicados
Publisher
Cancer Biology and Therapy(4)
Clinical Cancer Research(4)
Bionatura(3)
Frontiers in Pharmacology(3)
Seminars in Oncology(3)
Chronic vaccination with a therapeutic egf-based cancer vaccine: A review of patients receiving long lasting treatment
ArticleAbstract: Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despiPalabras claves:Cancer Vaccines, chronic vaccination, EGF, eGFRAutores:González G., Lage Davila A., Tania CrombetFuentes:scopusCombining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer
ArticleAbstract: An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapyPalabras claves:cancer vaccine, EGF, NSCLCAutores:Bárbara Wilkinson, Carmen Elena Viada, Fleites G., González G., González M.J., Lage Davila A., Leonard I., Mazorra Z., Neninger Vinageras E., Pereda S., Tania Crombet, Verdecia B.G.Fuentes:scopusAssociations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusAugmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusAnti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusAnti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs and the wound healing process
ReviewAbstract: Cutaneous wound healing is a complex process involving blood clotting, inflammation, tissue formatioPalabras claves:CETUXIMAB, Cimavax, Erlotinib, Gefitinib, Her-1 vaccine, nimotuzumab, PanitimumabAutores:Casacó Parada A.R., Fernández A., Fuente D., Ledón N., Tania CrombetFuentes:scopusAntiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody
ArticleAbstract: The epidermal growth factor receptor (EGFR) proto-oncogene is frequently overexpressed in tumors ofPalabras claves:Angiogenesis, Epidermal growth factor receptor (EGFR), H-R3, Monoclonal antibody, Signal inhibitorsAutores:Pérez R., Rak J., Tania Crombet, Viloria-Petit A.Fuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusA novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
ArticleAbstract: Background: There is evidence of a relationship between epidermal growth factor (EGF) and tumor cellPalabras claves:cancer vaccine, Epidermal growth factorAutores:Catala M., González G., Gonzalez Y.S., Guillén-Nieto G.E., Hernández J.C., Lage Davila A., Marinello P., Mirabal V., Tania CrombetFuentes:scopusA pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopus